Research Studies - MyMedi.ca

Studies Open for Participation

Medical Cannabis Real-World Evidence Study by UHN

What is a Real-world Evidence Study?

Medical Cannabis Real World Evidence is a research study to understand the effects of medical cannabis over 6 months in adult patients with chronic pain, epilepsy or issues with sleep, anxiety or depression.

Patients use strains of medical cannabis available on MyMedi.ca website.

Patients track their symptoms - using standard questionnnaires.

Why should I participate?

This is the first study of its kind and will include patients across Canada! It will give researchers valuble information on the use of medical cannnabis as a treatment option.

I am a Patient I am a Healthcare Professional

Real-World Evidence on Medical Cannabis in Pediatrics

An observational study by the Canadian Collaborative for Childhood Cannabinoid Therapeutics (C4T)

We’re asking parents/caregivers of children using medical cannabis to join an important Canadian study to learn about the long-term safety and benefits for kids.

Participants might be eligible if they have a child between the ages of 3 to 17 years old with a medical cannabis authorization from a healthcare provider. Caregivers will complete a consent form as well as a an enrollment medical assessment questionnaire, and online questionnaires sent by email at: 3, 6, 12 and 18 weeks, as well as 6, 12, 18 and 24 months. Caregivers will receive an honorarium for their time.

Interested in joining the study? Click here for more info!

Study website: https://www.medcannkids.ca/can-rwe

Pilot Phase II Clinical Study Osteoarthritis Pain

A multicentre pilot study on oral cannabinoids for osteoarthritic pain by the Pain Research Unit at University Health Network, sponsored by Avicanna Inc.

The study is led by Hance Clarke, MD, PhD, FRCPC, Medical Director of the Pain Research Unit and clinician at the University Health Network, and aims to evaluate the effectiveness of oral cannabinoid extracts for osteoarthritic pain. The blinded, randomized, placebo-controlled multicentre trial will assess the feasibility of using CBD and THC capsules in patients with hip and/or knee osteoarthritis, focusing on outcomes related to pain interference, patient enrollment, protocol adherence, and data completeness. The internal pilot study is anticipated to begin in Fall 2025 and is funded by a Canadian Institutes of Health Research (CIHR) grant. The oral capsules used in the trial are proprietary CBD and THC formulations provided by Avicanna Inc., manufactured under Good Manufacturing Practices (GMP).

Completed Studies

Observational Real-world Evidence Study

Using RHO Phyto™ Cannabigerol (“CBG”) Transdermal Gel on patients with musculoskeletal pain and inflammation

The RWE study evaluated patient-reported efficacy of the RHO Phyto CBG Transdermal Gel containing 2% cannabidiol (“CBD”) and 1% CBG on a range of clinical conditions including arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, muscle and joint pain, localized pain, muscular and structural injuries, and post-surgical pain. Seventy-one participants completed baseline testing and a follow up at 1-month including demographic, medical history, medication use and two standardized symptom questionnaires.

Retrospective Observational Real-world Evidence Study

Using RHO Phyto™ Ultra CBD Topical Cream on patients with epidermolysis bullosa

The study was led by Elena Pope, MD, M.Sc., FRCPC, Head of Dermatology at The Hospital for Sick Children in Toronto and evaluated the tolerability and efficacy of RHO Phyto™ Ultra CBD Topical Cream in patients with epidermolysis bullosa. The retrospective cohort study evaluated the reported and documented responses related to wound healing, pain, and itch end points through images for study purposes to examine and evaluate the effect of RHO Phyto™ branded Ultra CBD Topical Cream on wound healing. The RHO Phyto™ branded Ultra CBD Topical Cream is an oil based 3% CBD localized cream developed to target dermatology conditions.

Want to learn more?

If you are interested in learning more about this study, feel free to contact our Patient Support Team!

FAQ’s

Frequently Asked Questions

What is a Real-World Evidence (RWE) Study?

An RWE is a type of observational study that looks at how medical cannabis is used, its safety-profile, and overall effectiveness in a real-world setting. These studies can gather information from various sources like electronic health records, healthcare databases, and through patient surveys. For example, RWE studies looking at medical cannabis might use standardized surveys to understand how it affects common symptoms such as anxiety, depression, sleep, and pain.

How can real-world evidence studies help?

Provide the opportunity to study the effects of medical cannabis products on different conditions or symptoms
These studies can help provide more insight on the safety and effectiveness of medical cannabis in different populations that weren’t covered in a clinical trial and evaluate patients over a longer period of time in a real-world setting
RWE studies can capture the effectiveness of interventions like medical cannabis, where the effective dose, product and route of administration may differ person to person
Track the use of other medications and burden of diseases over time

How can I find out about upcoming studies that MyMedi.ca is supporting?

For information on Real World Evidence studies that MyMedi.ca and Avicanna are currently supporting or have previously been involved in, please contact us at support@mymedi.ca

Can I refer a friend or family member to participate in these studies?

If eligible, patients need to be enrolled in these studies by their prescriber. Interested patients should speak with their prescriber about the study, and have their prescriber follow up for more information.

How can I become a MyMedi.ca patient?

We are always interested in supporting our patients please send us an email at support@mymedi.ca